A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...

The cost–effectiveness of antiviral therapies ranged from cost savings to more than US$130,000 per quality-adjusted life-year (QALY) for influenza treatment, from GB£9000 to more than £1 ...

The antiviral baloxavir significantly reduced household transmission of influenza compared with placebo. The drug showed consistent effects across age groups, virus types, and countries, with no ...

Background The large-scale deployment of antiviral drugs from the Strategic National Stockpile during the 2009 H1N1 influenza response provides a unique opportunity to study local public health ...

Pneumagen has announced the publication of phase 2 data showing its antiviral therapy, Neumifil, significantly reduced ...

Influenza A (H1N1)pdm09 virus resistance to baloxavir, oseltamivir and sialic acid mimetics in single and dual therapies: Insights from human airway epithelia and murine models. Antiviral Res. 2025 ...

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as ...